Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial

Key Points

• Lower extremity complications are significant when assessing treatment options for type 2 diabetes.
• A notable focus on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors shows emerging trends.
• Observational analysis reveals the comparative safety profiles of different diabetes medications through real-world data.
• Implications highlight the necessity for individualized treatment plans based on complication risk.